Drug intelligence / Profile preview

WTX221

Development stage: Phase 1
Lead developer: Westlake Therapeutics
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

WTX221 is an investigational erythrocyte-conjugated **urate oxidase** therapy being evaluated for refractory gout with tophi. It consists of urate oxidase molecules displayed on the surface of red blood cells, a design intended both to enzymatically reduce circulating uric acid and to leverage the tolerogenic properties of erythrocytes to induce antigen-specific immune tolerance to urate oxidase. An exploratory early-phase clinical study evaluated repeated WTX221 infusions together with a single dose of cyclophosphamide to support immune-tolerance induction.

Targets

UOX (Urate oxidase)

Beyond the preview

Go deeper on WTX221.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WTX221.

Explore the full profile